Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab 300 mg auto-injector versus placebo in adults with moderate to severe plaque psoriasis
2018-000518-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Secukinumab 300 mg auto-injector with Placebo (2 arms). Primary endpoints: PASI 75 response at Week 12 and IGA mod 2011 score 0 or 1 response at Week 12. Started Nov 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-000518-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000518-39.